Ex-Div Reminder for Guggenheim Strategic Opportunities Fund (GOF)

Looking at the universe of stocks we cover at Dividend Channel, on 11/12/14, Guggenheim Strategic Opportunities Fund (GOF) will trade ex-dividend, for its monthly dividend of $0.1821, payable on 11/28/14. As a percentage of GOF's recent stock price of $21.88, this dividend works out to approximately 0.83%, so look for shares of Guggenheim Strategic Opportunities Fund to trade 0.83% lower — all else being equal — when GOF shares open for trading on 11/12/14.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for GOF, showing historical dividends prior to the most recent $0.1821 declared by Guggenheim Strategic Opportunities Fund:

GOF+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from GOF is likely to continue, and whether the current estimated yield of 9.99% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of GOF shares, versus its 200 day moving average:

Guggenheim Strategic Opportunities Fund 200 Day Moving Average Chart

Looking at the chart above, GOF's low point in its 52 week range is $19.13 per share, with $22.60 as the 52 week high point — that compares with a last trade of $21.87.

In Monday trading, Guggenheim Strategic Opportunities Fund shares are currently up about 0.1% on the day.

More from Stocks

PG&E Falls After Second Power-Line Failure

PG&E Falls After Second Power-Line Failure

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Pfizer Shares Jump on Monday After Company Signals Higher Price Push

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

Bulls Stampeded by Bears as FAANG Stocks Get Trampled

Apple Stock Falls Some 4% on Reports of iPhone Production Cuts

Apple Stock Falls Some 4% on Reports of iPhone Production Cuts

Tech Selloff Could Work in Favor of Pharmaceutical Stocks

Tech Selloff Could Work in Favor of Pharmaceutical Stocks